The correct way and dosage of tenofovir alafenamide fumarate tablets (Vemlidy)

Tenofovir alafenamide fumarate tablets (Vemlidy/Vemlidy) is a once-daily oral anti-hepatitis B drug. Scientific and regular medication is the key to ensuring efficacy. The recommended dose is 25mg taken orally daily, and should be taken with food to improve drug absorption. Eating can promote the dissolution of drugs in the intestine, allowing the active ingredients to enter the blood circulation more efficiently, thereby achieving stable antiviral concentrations.

Before starting treatment, doctors will conduct a comprehensive assessment of the patient, including hepatitis B viral load, liver function status, and whether there is concurrent HIV infectionHIV infection. If the test shows the presence of HIV infection, tenofovir alafenamide fumarate tablets must not be used alone, otherwise it may lead to viral resistance or reduced efficacy. For patients with only HBV infection, treatment can be started directly at the recommended dose.

During the period of taking the medicine, it needs to be taken at a fixed time every day to keep the drug concentration in the body stable. If you miss a dose due to special reasons, you should take it as soon as possible within 24 hours; if it is close to the next dose time, there is no need to increase the dose. Long-term regular medication is the core to achieve sustained suppression of the virus.

To ensure the safety of medication, patients should regularly detect renal function indicators, including serum creatinine, creatinine clearance, urine glucose, urine protein and serum phosphorus, before the start of treatment and during treatment. These tests help doctors assess the metabolic capacity of the kidneys and detect early adverse reactions in a timely manner. For patients with chronic kidney disease, doctors may appropriately adjust the frequency of monitoring or evaluate whether to continue use.

During medication, you should also pay attention to changes in liver function, especiallyALT, AST and other indicators. Some patients may experience mild fluctuations in the early stages of treatment, which is a common phenomenon during the viral clearance process. If liver enzymes continue to rise or obvious symptoms occur, a timely review should be conducted and the plan should be adjusted under the guidance of a doctor.

Reference materials:https://www.vemlidyhcp.com/